MRNA vs. JNJ

In the year-to-date period, MRNA achieves a -14.02% return, which is significantly lower than JNJ's 8.03% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and Johnson & Johnson (JNJ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current MRNA Sharpe Ratio is -0.88, which is lower than the JNJ Sharpe Ratio of 0.22. The chart below compares the historical Sharpe Ratios of MRNA and JNJ, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

MRNA has not paid dividends to shareholders, while JNJ's dividend yield for the trailing twelve months is around 3.20%.

The maximum MRNA drawdown since its inception was -93.70%, which is greater than JNJ's maximum drawdown of -52.60%. Use the drawdown chart below to compare losses from any high point for MRNA and JNJ. For additional features, visit the drawdowns tool.

Moderna, Inc. (MRNA) has a higher volatility of 24.90% compared to Johnson & Johnson (JNJ) at 5.79%. This indicates that MRNA's price experiences larger fluctuations and is considered to be riskier than JNJ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Moderna, Inc. and Johnson & Johnson. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.